Clinical proteomics: Insights from IGF-I

Jakob Albrethsen; Hanne Frederiksen; Trine Holm Johannsen; Anna-Maria Andersson; Anders Juul

doi:10.1016/j.cca.2017.11.034

Clinical proteomics: Insights from IGF-I

Jakob Albrethsen, Hanne Frederiksen, Trine Holm Johannsen, Anna-Maria Andersson, Anders Juul

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

Original language	English
Journal	Clinica chimica acta; international journal of clinical chemistry
Volume	477
Pages (from-to)	18-23
Number of pages	6
ISSN	0009-8981
DOIs	https://doi.org/10.1016/j.cca.2017.11.034
Publication status	Published - Feb 2018

Keywords

Chromatography, High Pressure Liquid
Humans
Insulin-Like Growth Factor I/analysis
Mass Spectrometry
Protein Isoforms
Proteomics

Access to Document

10.1016/j.cca.2017.11.034

Cite this

@article{16ffdf0a7fc745b1bfc41c8bad1a4975,

title = "Clinical proteomics: Insights from IGF-I",

abstract = "Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.",

keywords = "Chromatography, High Pressure Liquid, Humans, Insulin-Like Growth Factor I/analysis, Mass Spectrometry, Protein Isoforms, Proteomics",

author = "Jakob Albrethsen and Hanne Frederiksen and Johannsen, {Trine Holm} and Anna-Maria Andersson and Anders Juul",

year = "2018",

month = feb,

doi = "10.1016/j.cca.2017.11.034",

language = "English",

volume = "477",

pages = "18--23",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

TY - JOUR

T1 - Clinical proteomics

T2 - Insights from IGF-I

AU - Albrethsen, Jakob

AU - Frederiksen, Hanne

AU - Johannsen, Trine Holm

AU - Andersson, Anna-Maria

AU - Juul, Anders

PY - 2018/2

Y1 - 2018/2

N2 - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

AB - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.

KW - Chromatography, High Pressure Liquid

KW - Humans

KW - Insulin-Like Growth Factor I/analysis

KW - Mass Spectrometry

KW - Protein Isoforms

KW - Proteomics

U2 - 10.1016/j.cca.2017.11.034

DO - 10.1016/j.cca.2017.11.034

M3 - Review

C2 - 29196187

SN - 0009-8981

VL - 477

SP - 18

EP - 23

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

ER -

Clinical proteomics: Insights from IGF-I

Abstract

Keywords

Access to Document

Fingerprint

Cite this